Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25865022 | 0.93 | ALDH1A1 (0.46) | TP53MAPTSMN1; SMN2THRBTDP1 | |
| SCHEMBL22314498 | 0.89 | MAPT (0.53) | TP53MAPTSMN1; SMN2THRBTDP1 | |
| SCHEMBL22314500 | 0.89 | TP53 (0.44) | TP53MAPTSMN1; SMN2THRBTDP1 | |
| SCHEMBL22314889 | 0.88 | TSPO (0.46) | ALDH1A1KMOTSPO | |
| SCHEMBL25868217 | 0.88 | MAPT (0.46) | TP53MAPTSMN1; SMN2THRBTDP1 | |
| SCHEMBL22314464 | 0.86 | ALDH1A1 (0.50) | TP53MAPTSMN1; SMN2THRBTDP1 | |
| SCHEMBL25865003 | 0.86 | TSPO (0.47) | ALDH1A1KMOTSPO | |
| SCHEMBL22314474 | 0.86 | KMO (0.46) | TP53MAPTSMN1; SMN2ALDH1A1KMO | |
| SCHEMBL22315058 | 0.85 | MAPT (0.47) | TP53MAPTSMN1; SMN2THRBTDP1 | |
| SCHEMBL25868038 | 0.85 | ALDH1A1 (0.46) | TP53MAPTSMN1; SMN2THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | TP53 4487/4885MAPT 670/4885SMN1; SMN2 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.